{"text": ["What's", "in", "Store", "for", "Ligand", "(LGND)", "This", "Earnings", "Season?"], "created_at": "2018-02-19 17:07:23"}
{"text": ["What's", "in", "Store", "for", "Ligand", "(LGND)", "This", "Earnings", "Season?"], "created_at": "2018-02-19 17:07:23"}
{"text": ["Celgene", "Reports", "Positive", "Data", "on", "Dermatology", "Drug", "Otezla"], "created_at": "2018-02-19 16:08:40"}
{"text": ["Celgene", "Reports", "Positive", "Data", "on", "Dermatology", "Drug", "Otezla"], "created_at": "2018-02-19 16:08:40"}
{"text": ["AstraZeneca's", "(AZN)", "Imfinzi", "Gets", "FDA", "Nod", "for", "Label", "Expansion"], "created_at": "2018-02-19 16:08:22"}
{"text": ["AstraZeneca's", "(AZN)", "Imfinzi", "Gets", "FDA", "Nod", "for", "Label", "Expansion"], "created_at": "2018-02-19 16:08:22"}
{"text": ["Kymriah", "May", "Emerge", "as", "a", "Robust", "Treatment", "Option", "in", "DLBCL", "Indication"], "created_at": "2018-02-19 15:31:51"}
{"text": ["MEDIA", "LINK-Novartis", "CEO", "is", "using", "data", "science", "to", "revolutionize", "its", "drug-development", "pipeline", "-WSJ"], "created_at": "2018-02-19 14:44:04"}
{"text": ["Novartis\u2019", "Kymriah:", "The", "First", "Gene", "Therapy", "to", "Be", "Approved", "in", "the", "US"], "created_at": "2018-02-19 14:02:53"}
{"text": ["Is", "AbbVie", "or", "Gilead", "Sciences", "Stock", "a", "Better", "Buy?"], "created_at": "2018-02-19 13:08:38"}
{"text": ["Is", "AbbVie", "or", "Gilead", "Sciences", "Stock", "a", "Better", "Buy?"], "created_at": "2018-02-19 13:08:38"}
{"text": ["GlaxoSmithKline\u2019s", "Business", "Segments", "in", "4Q17"], "created_at": "2018-02-19 12:36:03"}
{"text": ["Cosentyx", "May", "Change", "Disease", "Progression", "for", "Ankylosing", "Spondylitis"], "created_at": "2018-02-19 12:34:01"}
